Brief: Allena Pharmaceuticals Provides Update on Clinical Development Programs
12/07/2021 13:16
July 12 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS INC - ON TRACK TO START TWO PHASE
2A
STUDIES FOR ALLN-346 IN Q3 2021 WITH INITIAL DATA EXPECTED IN Q4
2021
* ALLENA PHARMACEUTICALS INC - RELOXALIASE ADVANCING IN
URIROX-2
PIVOTAL PHASE 3 STUDY; REVISED INTERIM ANALYSIS NOW TARGETED FOR
Q1 2022
Source text for Eikon: ID:nGNX2rjCkX
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing